# Transgenic and Chimeric Mouse Core

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2021 · $119,341

## Abstract

The accelerating incidence of diabetes and metabolic disorders and the continuing high prevalence of
endocrine disorders in the American population demands continued exploration of a broad array of
corresponding mechanistic pathways, pathophysiologic sequelae, and potential therapeutic approaches. In
many cases these investigations can be accomplished most efficiently using model systems established in
intact animals. The use of mouse models in these pursuits is now well established for its power, feasibility, and
enormous potential. Creation of such models, by directed alterations of the mouse genome, is an essential
component of an overall research effort in diabetes, obesity, and metabolic disorders. The Transgenic and
Chimeric Mouse Facility (TCMF) provides investigators of the University of Pennsylvania Diabetes and
Endocrinology Research Center (DRC) with the ability to carry out these studies in a cost effective and efficient
manner. The TCMF applies state-of-the-art equipment and technology by a group of dedicated and highly
skilled technical staff to this effort. The major services of the Core include generation of transgenic mice by
DNA pronuclear injection, creation of chimeric mice by ES cell blastocyst injections, direct genome
mutation/editing/modifications by targeted endonuclease (TALEN and Crispr-CAS) technologies, assisted (in
vitro) fertilization, cryopreservation, long-term cryostorage, and shipping of frozen embryos or sperm to/from
other facilities. The Core uses multiple microinjection platforms, laser-assisted technologies, state-of-the-art
cryopreservation of gametes and embryos, and in vitro fertilization based line re-derivation to facilitate these
goals. The facility consists of a microinjection suite, an adjacent dedicated cage room, and an off-site and
highly secure cryopreservation storage facility. All functions, from ordering services, to following workflow, to
storing and sending out lines are on-line and can be monitored in real-time. These efforts contribute
substantially to the overall productivity of the members of the DRC and enhance the strength and relevance of
their studies to intact mammalian systems. This maximizes the applicability of these studies to human disease
and to the expansion of therapeutic modalities.

## Key facts

- **NIH application ID:** 10137229
- **Project number:** 5P30DK019525-45
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** STEPHEN Aaron LIEBHABER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $119,341
- **Award type:** 5
- **Project period:** 1997-03-01 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10137229

## Citation

> US National Institutes of Health, RePORTER application 10137229, Transgenic and Chimeric Mouse Core (5P30DK019525-45). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10137229. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*